EZH2 and colorectal cancer: In patients with high MALAT1 expression, it was found that MALAT1 binds EZH2 to the CDH1 promoter and inhibits miR-218 during oxaliplatin treatment, indirectly promoting EMT, metastasis, and chemoresistance of colorectal cancer cells.